

1 A nationwide survey on unilateral moyamoya disease in Japan

2

3 Kentaro HAYASHI, MD; Nobutaka HORIE, MD; Tsuyoshi Izumo, MD; Izumi

4 NAGATA, MD

5

6 Department of Neurosurgery, Nagasaki University School of Medicine

7

8

9 Kentaro Hayashi

10 Department of Neurosurgery

11 Nagasaki University School of Medicine

12 Sakamoto 1-7-1, Nagasaki city, Nagasaki 852-8501, Japan

13 Tel: +81-95-819-7375

14 Fax: +81-95-819-7378

15 E-mail: [kenkuni@nagasaki-u.ac.jp](mailto:kenkuni@nagasaki-u.ac.jp)

16

1 **Acknowledgement**

2 The authors would like to express their heartfelt thanks to the doctors who devoted their  
3 time to this investigation.

4

5 **Source of Funding**

6 This study was supported by a Grant-in-Aid for Research Committee on Moyamoya  
7 Disease (Spontaneous Occlusion of the Circle of Willis) from the Ministry of Health,  
8 Labor and Welfare of Japan.

9

10 **Disclosure**

11 None.

12

13

1 Full title: A nationwide survey on unilateral moyamoya disease in Japan  
2  
3 Cover title: Survey on unilateral moyamoya disease  
4  
5 Number of Table: 1  
6  
7 Number of Figure: 5 (black and white)  
8  
9 Key words; moyamoya disease, unilateral moyamoya disease, nationwide survey,  
10 epidemiology, intracranial hypoperfusion, stroke, intracerebral hemorrhage, children  
11  
12

1 **Abstract**

2

3 **Objective** Moyamoya disease (MMD) is an unique occlusive disease of the bilateral  
4 internal carotid arteries; compensation for occlusion results in rich arterial collaterals at  
5 the base of the brain. The clinical features of unilateral MMD, confirmed by typical  
6 angiographic evidence of MMD unilaterally and normal or equivocal contralateral  
7 findings, are not well known. To identify the clinical features of unilateral MMD in  
8 Japan, a nationwide survey was conducted.

9 **Patients and Methods** The questionnaire was directly mailed to 241 departments that  
10 reported treating unilateral MMD patients in a primary survey. We ascertained the sex,  
11 age, family history, clinical manifestation, radiological findings, treatments, course of  
12 the disease, and daily activity of unilateral MMD patients.

13 **Results** A total of 114 departments replied to the questionnaire. The data of 203 patients  
14 (118 female and 85 male; female to male ratio 1.4) were registered and analyzed. The  
15 mean age was 40.2 years old with a peak occurring in the fifties. Twenty-one patients  
16 (10.7%) exhibited familial MMD. The clinical symptoms are motor weakness 57  
17 (26.8%), headache 37 (17.4%), transient ischemic attack 35 (16.4%), and no symptom  
18 30 (14.1%). The MMD types determined by imaging included ischemic type in 64  
19 patients (32.5%), bleeding type in 51 (25.9%), and normal in 82 (41.6%). The  
20 development of moyamoya vessels was mild in 78 patients (43.9%) and most patients  
21 (81.1%) were accompanied with cerebral hypoperfusion. Medical treatment or vascular  
22 reconstruction was employed for the more than half of the patients. **Conclusion** The

1 clinical feature of unilateral MMD were revealed in this nationwide study. Unilateral  
2 MMD was predominant in adults and the development of moyamoya vessel was  
3 relatively less prevalent.  
4

1 **1. Introduction**

2  
3 Moyamoya disease (MMD) is characterized by idiopathic steno-occlusion at the  
4 terminal portion of the internal carotid artery (ICA) with concomitant abnormal vascular  
5 networks (1). Whether unilateral lesion, confirmed by typical angiographic evidence of  
6 MMD unilaterally and normal or equivocal contralateral findings, is an early form of  
7 definite MMD remains controversial (2-5). The progression of the contralateral side in  
8 patients with predominantly unilateral MMD is reported especially in young patients (3).  
9 Thus, familial occurrence of unilateral MMD was observed in the definite MMD  
10 pedigree (6, 7). On the other hand, moyamoya-like vasculopathy more often tend to  
11 occur unilaterally in the genetic or acquired syndromes (8, 9).

12 We conducted a nationwide epidemiological survey on MMD, unilateral  
13 MMD, and quasi-MMD in 2006 (10). The annual incidence rate of MMD and unilateral  
14 MMD are 1.13/100,000, and 0.23/100,000 respectively, and the prevalence is  
15 5.22/100,000 and 0.66/100,000, respectively. Because unilateral MMD is quite a rare  
16 disease, single center studies are not feasible to identify the associated clinical features.  
17 Based on this earlier study, we conducted a secondary survey to determine the clinical  
18 features of unilateral MMD.

19  
20 **2. Materials and Methods**

21  
22 The criteria prepared by the Research Committee on Moyamoya disease (Spontaneous

1 Occlusion of the Circle of Willis) of Japan were used for the clinical diagnosis of MMD.  
2 A diagnostic algorithm was used to appropriately diagnosis of each type of MMD (Fig.  
3 1A). “Bilateral MMD” is bilateral ICA terminal steno-occlusion with bilateral  
4 development of moyamoya vessels. “Unilateral MMD” is unilateral ICA terminal  
5 steno-occlusion with development of moyamoya vessels. “Definite MMD” describes  
6 adult cases of bilateral MMD. In pediatric cases, “unilateral MMD” is also considered  
7 to be “definite MMD” if steno-occlusion is indentified on another side of the ICA  
8 terminal. The questionnaire was directly mailed to 241 departments that reported  
9 answered treating unilateral MMD patients in the primary survey. We ascertained the  
10 sex, age, associated disorders, clinical manifestation, radiological findings (subtype,  
11 degree of moyamoya vessels, location of steno-occlusive lesion, and Suzuki’s  
12 angiographic stage in each sides), cerebral blood flow (CBF), treatments including  
13 medical and surgical methods, course of the disease, initial and follow-up modified  
14 Rankin Scale (mRS), follow-up period, follow-up imaging studies and the results, and  
15 family history of quasi-MMD patients. For the evaluation of moyamoya vessels, typical  
16 moyamoya vessels observed in definite MMD was categorized as severe. Each  
17 angiographical example was enclosed (Fig. 1B-D). The medical fees of definite MMD  
18 patients were supported by a Grant-in-Aid for Intractable Diseases from the Ministry of  
19 Health, Labor and Welfare of Japan. Unilateral MMD patients received this support on a  
20 case by case basis.

21

22

### 3. Results

1  
2 A total of 114 departments replied to the questionnaire (response rate; 47.3%). The data  
3 of 203 patients (85 male and 118 female) were registered and analyzed. The mean age  
4 was 40.2 years old with an upper peak in the fifties and a lower peak among children  
5 (Fig. 2). Twenty-one patients (10.7%) exhibited familial MMD.  
6 The initial clinical manifestations included motor weakness in 57 patients (26.8%),  
7 headache in 37 patients (17.4%), transient ischemic attack in 35 patients (16.4%), and  
8 no symptoms in 30 patients (14.1%) (Table 1). The imaging study subtypes included the  
9 ischemic type in 64 patients (32.5%), bleeding type in 51 patients (25.9%), and normal  
10 type in 82 patients (41.6%) (Fig. 3A). The development of moyamoya vessels were  
11 mild in 78 patients (43.9%), moderate in 42 patients (23.6%) and severe in 58 patients  
12 (32.6%) (Fig. 3B). The right side was involved in 109 cases (53.7%) and the left side  
13 was involved in 94 patients (46.3%). Steno-occlusive lesions were observed at the ICA  
14 in 134 patients (70.2%), the middle cerebral artery (MCA) in 41 patients (21.5%), the  
15 MCA and the anterior cerebral artery (ACA) in 15 patients (7.9%), and the ACA in 1  
16 patient (0.5%) (Fig. 3C). On the contralateral side, steno-occlusive lesions were  
17 observed at the ICA in 14 patients (8.4%), the MCA in 10 cases (6.0%), the MCA and  
18 the ACA in 2 patients (1.2%), and the ACA in 15 patients (9.0%) (Fig. 3D). Collateral  
19 from external carotid arteries developed in 23 patients (13.0%). In terms of cerebral  
20 circulation, hypoperfusion was observed in 101 patients (63.5%) and vasoreactivity was  
21 impaired in 28 patients (17.6%).

22 Antithrombotic agents were given to 86 patients (40.0%), anticonvulsant were



1 given to 21 patients (9.8%), and antihypertensive drugs were given to 20 patients  
2 (9.3%) (Fig. 4A). Eighty-two patients (38.1%) were not medically treated. Vascular  
3 reconstruction was performed on 110 patients (89 patients underwent direct  
4 reconstruction; 44.3%, 21 patients underwent indirect reconstruction; 10.4%) (Fig.  
5 4B). Eighty-three patients (41.3%) were not treated surgically. During follow-up, 42  
6 patients (23.3%) experienced improved symptoms, 127 patients (70.6%) experienced no  
7 change and symptoms worsened in 3 patients (1.7%) (Fig. 5A). Among the 42 patients  
8 showing symptom improvement, 35 patients (83.3%) had been treated surgically and 28  
9 patients (66.7%) had been treated medically. Cerebral hemorrhage occurred in 5 patients  
10 (2.8%). In addition, disease progressed in the contralateral side in 3 patients (1.7%).  
11 Both initial and follow-up mRS scores are shown in Figure 5B. Approximately 80% of  
12 patients had an initial mRS score of 0-2 and were relatively better during follow-up.

13 Finally, the medical fees of 84 patients (54.5%) were supported by the  
14 government.

15

16

#### 4. Discussion

17

18 Unilateral lesions, confirmed by typical angiographic evidence of MMD unilaterally  
19 and normal or equivocal contralateral findings, have been defined as probable MMD (3).  
20 The term of “probable” may be confusing because this may indicate poor diagnoses or  
21 insufficient examination of the patient. Therefore, per the MMD guidelines, published  
22 in 2011, the term “unilateral MMD” replaces the term “probable” (11).

1           Unilateral lesions frequently develop to bilateral lesions in pediatric patients  
2     (2, 12) . Familial occurrence has been reported in approximately 10% of MMD  
3     patients (13-16). In this unilateral MMD study, the prevalence of familial occurrence  
4     was 10.7%. The coincidence of unilateral and definite MMD within a single family  
5     indicates that they reflect different phenotypes cause by the same genetic defects (6). In  
6     unilateral cases, there was a predominance of female cases and it has been reported that  
7     the female to male ratio of definite case was approximately 2-fold (14, 16). In this study,  
8     that female to male ratio of unilateral cases was 1.4. In terms of patient ages, we  
9     observed two peak patterns in the age distribution in unilateral cases as definite MMD.  
10    Consistent with previous reports, the adult onset rate is higher in unilateral cases than in  
11    definite cases (3, 4, 17, 18). Acquired disease such as atherosclerosis may be a cause of  
12    the moyamoya like steno-occlusive disease. It is well known that atherosclerosis  
13    predominantly occurs elderly males. The results of the sex and age analyses indicate  
14    that unilateral MMD might be influenced by acquired diseases including  
15    atherosclerosis.

16           The clinical manifestations of unilateral MMD are divided into focal sign and  
17    non-specific symptoms such as headache and unconsciousness. In this study, half of the  
18    patients had focal signs and while the remaining patients had non-specific symptoms or  
19    were asymptomatic. From our experience, unilateral MMD tends to be found with  
20    coincidentally (19). The imaging subtype study included ischemic type in 64 patients  
21    (32.5%), bleeding type in 51 patients (25.9%), and normal type (only vascular lesion) in  
22    82 patients (41.6%). It is well known that the pediatric patients presenting with ischemic

1 attack and adult patients tend to suffer from intracranial bleeding (14, 16). Although  
2 unilateral MMD was predominant in adults, bleeding was relatively less common.  
3 Recent MMD diagnostics using magnetic resonance (MR) imaging and MR  
4 angiography makes it possible to detect asymptomatic patients (20).

5 Steno-occlusive lesions were mainly observed in the ICA. This feature  
6 differentiates unilateral MMD from idiopathic MCA occlusion. Regarding with the  
7 contralateral side, ACA or MCA were occasionally involved. Kelly et al. reported that  
8 unilateral patients with contralateral equivocal arterial stenotic changes are at an  
9 increased risk of disease progression (4). Because the development of moyamoya  
10 vessels is the most important finding in the diagnosis of MMD, we evaluated the degree  
11 of moyamoya vessels development. The development of moyamoya vessels was mild or  
12 moderate in two-thirds of the patients. Thus, collateral from the external carotid arteries  
13 was observed in only 13% of patients. Lower levels of collateral vessel development  
14 occurred in unilateral MMD patients compared with definite MMD patients. CBF was  
15 impaired in approximately 80% of cases. It is speculated that the CBF was mainly  
16 evaluated with single photon emission computed tomography (SPECT) because SPECT  
17 is widely used in Japan and MMD guideline recommend CBF measurement for the  
18 treatment of MMD (11).

19 Approximately 60% of patients were medically treated. Refracting cerebral  
20 hypoperfusion and antithrombotic agents were the most frequently employed medical  
21 treatments. Anticonvulsants were prescribed for symptomatic epilepsy. Because the age  
22 of the patients was relatively higher, they may also have arteriosclerosis or hypertension.

1 As a result, antihypertensive drugs would be indicated. Approximately 60% of patients  
2 were treated surgically. Because most cases occurred in adults, the incidence of direct  
3 bypass, most likely of the superficial temporal artery-MCA anastomosis, was much  
4 greater than indirect bypass such as encephalo-duro-arterio-synangiosis. This is a  
5 retrospective study and all treatments were chosen by the physicians. Interestingly, a  
6 significant proportion of patients were not treated medically or surgically.

7           During follow-up, the clinical status improved among 23.3% of patients.  
8 Clinical symptoms worsened in only 1.7% of patients in the lesion side and in only  
9 1.7% of patients in the contralateral side. Cerebral hemorrhage also occurred rarely.  
10 Activities of daily living were done independently in approximately 80% of patients  
11 initially and in approximately 90% of patients during follow-up.

12           The medical fees of patients with definite MMD were supported by the  
13 government. Doctors designated from each prefecture certified the diagnosis of the  
14 patient according to the MMD criteria. Although unilateral cases should not be certified  
15 as definite MMD, over half of the unilateral cases were certified as definite MMD cases  
16 in this study. Sympathy for the patients might be a cause of this violation.

17

18

## 5. Conclusions

19

20 In conclusion, the clinical features of unilateral MMD were determined by the analyses  
21 of a nationwide survey. Unilateral MMD was predominant in adults and the  
22 development of moyamoya vessels was relatively low.

1

2

### **Acknowledgement**

3 The authors would like to express their heartfelt thanks to the doctors who devoted their  
4 time to this investigation.

5

6

### **Source of Funding**

7 This study was supported by a Grant-in-Aid for Research Committee on Moyamoya  
8 Disease (Spontaneous Occlusion of the Circle of Willis) from the Ministry of Health,  
9 Labor and Welfare of Japan.

10

11

### **Disclosure**

12 None.

13

### **References**

14

15  
16 1) Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the  
17 circle of Willis ('moyamoya' disease). Research Committee on Spontaneous Occlusion  
18 of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare,  
19 Japan. Clin Neurol Neurosurg. 1997;99 Suppl 2:S238-S240

20

21 2) Hirotsune N, Meguro T, Kawada S, Nakashima H, Ohmoto T. Long-term follow-up  
22 study of patients with unilateral moyamoya disease. Clin Neurol Neurosurg. 1997;99

1 Suppl 2:S178-181

2

3 3) Houkin K, Abe H, Yoshimoto T, Takahashi A. Is "unilateral" moyamoya disease  
4 different from moyamoya disease? J Neurosurg. 1996;85:772-776

5

6 4) Kelly ME, Bell-Stephens TE, Marks MP, Do HM, Steinberg GK. Progression of  
7 unilateral moyamoya disease: A clinical series. Cerebrovasc Dis. 2006;22:109-115

8

9 5) Nagata S, Matsushima T, Morioka T, Matsukado K, Mihara F, Sasaki T, Fukui M.

10 Unilaterally symptomatic moyamoya disease in children: long-term follow-up of 20  
11 patients. Neurosurgery. 2006;59:830-836

12

13 6) Kusaka N, Tamiya T, Adachi Y, Katayama S, Namba S, Tokunaga K, Sugiu K, Date I,

14 Ohmoto T. Adult unilateral moyamoya disease with familial occurrence in two definite  
15 cases: a case report and review of the literature. Neurosurg Rev 2006;29:82-87

16

17 7) Mineharu Y, Takenaka K, Yamakawa H, Inoue K, Ikeda H, Kikuta KI, Takagi Y,

18 Nozaki K, Hashimoto N, Koizumi A. Inheritance pattern of familial moyamoya disease:

19 autosomal dominant mode and genomic imprinting. J Neurol Neurosurg Psychiatry  
20 2006;77:1025-1029

21

22 8) Horn P, Pfister S, Buelmann E, Vajkoczy P, Schmiedek P. Moyamoya-like

- 1 vasculopathy (moyamoya syndrome) in children. Childs Nerv Syst. 2004;20:382-391
- 2
- 3 9) Ishikawa T, Houkin K, Yoshimoto T, Abe H. Vasoreconstructive surgery for  
4 radiation-induced vasculopathy in childhood. Surg Neurol 1997;48:620-626
- 5
- 6 10) Hayashi K, Horie N, Suyama K, Izumi N. Epidemiological survey on moyamoya  
7 disease, unilateral moyamoya disease and quasi-moyamoya disease. Clinical Neurology  
8 and Neurosurgery 2013;115:930-933
- 9
- 10 11) Health Labour Sciences Research Grant for Research on Measures for Intractable  
11 Disease Research Committee on the Pathology and Treatment of Spontaneous  
12 Occlusion of the Circle of Willis. Guidelines for diagnosis and treatment of moyamoya  
13 disease (spontaneous occlusion of the Circle of Willis). Surgery for Cerebral Stroke  
14 2009;37 : 321-337
- 15
- 16 12) Kawano T, Fukui M, Hashimoto N, Yonekawa Y. Follow-up study of patients with  
17 "unilateral" moyamoya disease. Neurol Med Chir (Tokyo). 1994;34:744-747
- 18
- 19 13) Fukui M, Kono S, Sueishi K, Ikezaki K. Moyamoya disease. Neuropathology  
20 2000;20 Suppl:S61-S4
- 21
- 22 14) Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives.

- 1 Lancet Neurol. 2008;7:1056-1066.
- 2
- 3 15) Nanba R, Kuroda S, Tada M, Ishikawa T, Houkin K, Iwasaki Y. Clinical features of  
4 familial moyamoya disease. Childs Nerv Syst 2006;22:258-262
- 5
- 6 16) Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med.  
7 2009;360:1226-1237.
- 8
- 9 17) Ikezaki K, Inamura T, Kawano T, Fukui M. Clinical features of probable moyamoya  
10 disease in Japan. Clin Neurol Neurosurg 1997;99 Suppl 2:S173-S177
- 11
- 12 18) Kawano T, Fukui M, Hashimoto N, Yonekawa Y. Follow-up study of patients with  
13 "unilateral" moyamoya disease. Neurol Med Chir (Tokyo) 1994;34:744-747
- 14
- 15 19) Hayashi K, Suyama K, Nagata I. Clinical features of unilateral moyamoya disease.  
16 Neurol Med Chir (Tokyo). 2010;50:378-385
- 17
- 18 20) Kuroda S, Hashimoto N, Yoshimoto T, Iwasaki Y; Research Committee on  
19 Moyamoya Disease in Japan. Radiological findings, clinical course, and outcome in  
20 asymptomatic moyamoya disease: results of multicenter survey in Japan. Stroke  
21 2007;38:1430-1435



1 **Figure legends**

2 Fig. 1

3 A: A diagnostic algorithm of definite moyamoya disease, unilateral moyamoya disease  
4 and quasi-moyamoya disease. ICA indicates internal carotid artery. MMD indicates  
5 moyamoya disease.

6 B: Angiographical example of mild moyamoya vessels.

7 C: Angiographical example of moderate moyamoya vessels.

8 D: Angiographical example of severe moyamoya vessels.

9

10 Fig. 2 Distribution of the patients' age

11

12 Fig. 3

13 A: Subtype found by the imaging studies

14 B: Degree of the moyamoya vessels

15 C: Location of the steno-occlusion of the arteries (lesion side)

16 D: Location of the steno-occlusion of the arteries (contralateral side)

17

18 Fig. 4

19 A: Status of the medical treatment

20 B: Status of the surgical treatment

21

22 Fig. 5

- 1 A: Clinical status
- 2 L; lesion side, C; contralateral side
- 3 B: Initial and follow-up modified Rankin Scale scores

Fig. 1A






Fig. 1

B



C



D




Fig. 2





Fig. 3

A



B





Fig. 3

C



D





Fig. 4

A



B







Fig.5

A



B




Table 1 Clinical manifestation of unilateral moyamoya disease

	n	%
motor weakness	57	26.8
headache	37	17.4
TIA	35	16.4
consciousness disturbance	17	8
sensory disturbance	14	6.6
aphasia	12	5.7
other neurological deficit	8	3.8
seizure	3	1.4
asymptomatic	30	14.1

TIA; transient ischemic attack